Transgene's TG4010 NSCLC Development Program to Include Two Companion Tests | GenomeWeb

Transgene is using two companion tests, one being developed by Beckman Coulter and another by Ventana Medical Systems, to pick best responders to its investigational non-small cell lung cancer drug TG4010.

The immunohistochemistry test developed by Ventana will allow Transgene to identify patients expressing mucin 1-positive tumor cells in clinical trials. TG4010 was designed to target MUC1, and the IHC assay will be used to select patients to be enrolled in an upcoming Phase IIb/III trial for the drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.